The Development & Approval of Enhertu in Patients with Unresectable or Metastatic HER2-positive Breast Cancer
Time: 9:40 am
day: Day One
Details:
• Outlining the pre-clinical profile and mechanism of action of Enhertu ([Fam-] trastuzumab deruxtecan, DS-8201a, T-DXd)
• Reviewing clinical development leading to the approval of Enhertu
• Understanding the current development status of Enhertu
Speakers:
Dr. Gilles Gallant is an oncology expert with broad biotechnology and pharmaceutical experience in strategic cancer drug development, evaluation, and innovations. Gillesjoined DaiichiSankyo,Inc. (Basking Ridge, New Jersey) in 2017 as Vice President, Global Team Leader, Oncology Research &Development. Daiichi SankyoCancer Enterprise’s mission is to leverage world-class, innovative science and push beyond traditional thinking to create…Read more